Stay updated with breaking news from Nasdaq Stok. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating restated by analysts at Needham & Company LLC in a note issued to investors on Monday, Benzinga reports. They currently have a $22.00 price target on the stock. Needham & Company LLC’s price target would indicate a potential upside of 80.33% from the […]
Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Needham & Company LLC in a report released on Thursday, Benzinga reports. They presently have a $22.00 price objective on the stock. Needham & Company LLC’s target price indicates a potential upside of 72.41% from the company’s current […]
Stoke Therapeutics (NASDAQ:STOK – Free Report) had its price target hoisted by Needham & Company LLC from $14.00 to $22.00 in a research note released on Tuesday morning, Benzinga reports. The firm currently has a buy rating on the stock. STOK has been the subject of several other research reports. JPMorgan Chase & Co. increased […]
Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) has received a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year target […]
Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) insider Barry Ticho sold 10,000 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $4.80, for a total transaction of $48,000.00. Following the completion of the sale, the insider now owns 6,981 shares of the company’s […]